United States 119th Congress Status: In Committee Bipartisan · 11 R · 10 D cosponsors

S 932 — Give Kids a Chance Act of 2025

Last action — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced March 11, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 21 sponsors

    1 primary, 20 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (11 R · 10 D) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Give Kids a Chance Act of 2025This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.

Bill Text

How this bill changes current law

6 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill amends existing law to clarify and enhance the requirements for molecularly targeted pediatric cancer investigations and extends certain authorities related to pediatric drug development.

  • 21 U.S.C. 355c(a)(3)

    subparagraph (B) and (C) as subparagraphs (C) and (D), respectively; and → subparagraphs (C) and (D), respectively; and

    Redesignates existing subparagraphs to accommodate new amendments.

  • 21 U.S.C. 355c(a)(3)

    the investigations described in this paragraph is a molecularly targeted pediatric cancer investigation of— → the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of—

    Clarifies the description of the molecularly targeted pediatric cancer investigation.

  • 21 U.S.C. 355c(a)(3)

    and under section 262 of title 42 for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration, → or under section 351(k) of the Public Health Service Act for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration,

    Updates the references to align with current terminology in the Public Health Service Act.

  • 21 U.S.C. 355c(e)(1)

    The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).

    Mandates a determination by the Secretary on applicability of requirements before submission of an initial pediatric study plan.

  • 21 U.S.C. 355c(a)(1)

    No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be subject to the requirements of subparagraph (B).

    Clarifies the rule of construction regarding overlapping requirements for different types of applications.

  • 21 U.S.C. 360ff(b)(5)

    December 20, 2024, unless → September 30, 2029.

    Extends the deadline for issuing priority review vouchers for treatments of rare pediatric diseases.

Action History

  1. Introduced in Senate

  2. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 20 co-sponsors · 526 not signed on

Sponsors (1)

Co-sponsors (20)

Not signed on (526)

526 members have not signed on to this bill.

Show all 526 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare education health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 932 do?
Give Kids a Chance Act of 2025This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
Who sponsors S 932?
S 932 is sponsored by Mullin, Markwayne (Republican), Bennet, Michael F. (Democratic), Klobuchar, Amy (Democratic), Shaheen, Jeanne (Democratic), Marshall, Roger (Republican), Scott, Rick (Republican), Collins, Susan M. (Republican), Coons, Christopher A. (Democratic), Capito, Shelley Moore (Republican), Kelly, Mark (Democratic), Husted, Jon (Republican), Kim, Andy (Democratic), Sheehy, Tim (Republican), Moody, Ashley (Republican), Hickenlooper, John W. (Democratic), Duckworth, Tammy (Democratic), Boozman, John (Republican), Schiff, Adam B. (Democratic), Kennedy, John (Republican), Reed, Jack (Democratic), and Schmitt, Eric (Republican).
What is the current status of S 932?
This bill is in committee in the Senate. Introduced March 11, 2025. It must pass committee before a floor vote.
Where can I track S 932?
Track S 932 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 932

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 932

Last checked for changes 4 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →